Compare
Lite Strategy, Inc. vs Sunshine Biopharma Inc. vs Lifevantage Corp vs Incannex Healthcare Inc.
| Latest fiscal year | Lite Strategy, Inc. LITS | Sunshine Biopharma Inc. SBFM | Lifevantage Corp LFVN | Incannex Healthcare Inc. IXHL |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2026-06-30 | 2026-06-30 |
| Revenue | n/a | $36.31M | $182.59M | $0 |
| Revenue growth (YoY) | n/a | +4.1% | -20.1% | -100.0% |
| Gross margin | n/a | 33.8% | 77.6% | n/a |
| Operating margin | n/a | -17.2% | 3.3% | n/a |
| Net margin | n/a | -16.5% | 2.8% | n/a |
| Net income | -$71.15M | -$5.98M | $5.07M | -$19.30M |
| EPS (Diluted) | -$2.06 | n/a | $0.40 | -$1.66 |
| Operating cash flow | -$9.12M | -$5.33M | $10.24M | -$12.87M |
| Free cash flow | n/a | -$5.51M | $6.67M | -$12.88M |
| Cash & equivalents | $5.71M | n/a | n/a | $67.71M |
| Total assets | $42.69M | $30.08M | $62.11M | $72.98M |
| Total liabilities | $1.07M | $7.04M | $28.52M | $5.61M |
| Shareholders' equity | $41.62M | $23.04M | $33.59M | $67.37M |
| Return on year-end equity | -170.9% | -25.9% | 15.1% | -28.6% |
| Shares outstanding | 32.41M | 4.91M | 12.52M | 12.54M |
Revenue, most recent five fiscal years
| Fiscal year | Lite Strategy, Inc. | Sunshine Biopharma Inc. | Lifevantage Corp | Incannex Healthcare Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2025-06-30 | $36.31M Ended 2025-12-31 | $182.59M Ended 2026-06-30 | $0 Ended 2026-06-30 |
| 1 year earlier | $65.30M Ended 2024-06-30 | $34.87M Ended 2024-12-31 | $228.53M Ended 2025-06-30 | $86.0K Ended 2025-06-30 |
| 2 years earlier | $48.82M Ended 2023-06-30 | $24.09M Ended 2023-12-31 | $200.16M Ended 2024-06-30 | $12.0K Ended 2024-06-30 |
| 3 years earlier | $40.70M Ended 2022-06-30 | $4.35M Ended 2022-12-31 | $213.40M Ended 2023-06-30 | n/a |
| 4 years earlier | $34.80M Ended 2021-06-30 | $228.4K Ended 2021-12-31 | $206.36M Ended 2022-06-30 | n/a |